Effects of plant stanol and sterol esters on serum phytosterols in a family with familial hypercholesterolemia including a homozygous subject.
We studied the concentrations and ratios to cholesterol of noncholesterol sterols reflecting absorption (eg, campesterol) or synthesis (eg, lathosterol) of cholesterol off and on plant sterol and stanol ester spreads in serum and in different lipoproteins of a family with familial hypercholesterolemia, including heterozygous parents receiving no treatment and their homozygous offspring undergoing long-term treatment with statins and apheresis. Serum cholesterol levels were similar in the homozygous and heterozygous individuals, but the concentrations of sterols reflecting cholesterol absorption were as much as 10 times greater in the homozygous child than in the heterozygous parents, whereas the respective markers of cholesterol synthesis only tended to be higher. About 70% of squalene in the homozygous individual (60% in the heterozygous family members) and 85% to 90% of noncholesterol sterols (60%-80% in the heterozygous subjects) were transported by low-density lipoprotein. The ratios of absorption sterols to cholesterol were higher in high-density lipoprotein (HDL) than in very low-density lipoprotein (VLDL), whereas those of synthesis markers and plant stanols were highest in VLDL. The ratios of absorption sterols in serum were mostly lower than those in HDL but higher than in VLDL, whereas the ratios of synthesis sterols in serum were lower than they were in VLDL. Both spreads reduced serum total cholesterol by about 14% in the heterozygous family members and 9% in the homozygous individual. The sterol ester spread increased serum plant sterol concentrations (eg, campesterol in the homozygous family member increased from 5 to 9 mg/dL) and the ratios to cholesterol, but the stanol ester spread decreased them. Plant sterol esters seemed to similarly decrease serum cholesterol in this family with familial hypercholesterolemia, but the clinical role of increased plant sterol concentrations, almost doubled in the LDL of homozygous individuals, is not known.
Ketomaki
Anna
A
Division of Internal Medicine and Biomedicum Helsinki, University of Helsinki, FIN-00029 HUS, Helsinki, Finland.
Gylling
Helena
H
Miettinen
Tatu A
TA
D000328:Adult; D001781:Blood Component Removal; D002784:Cholesterol / Q000031:analogs & derivatives* / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood / Q000187:drug effects; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects / Q000302:isolation & purification; D004041:Dietary Fats / Q000008:administration & dosage; D004311:Double-Blind Method; D005260:Female; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000178:diet therapy* / Q000235:genetics; D000960:Hypolipidemic Agents / Q000008:administration & dosage* / Q000097:blood; D008297:Male; D008383:Margarine; D008875:Middle Aged; D010840:Phytosterols; D012855:Sitosterols / Q000008:administration & dosage* / Q000097:blood; D013185:Squalene / Q000378:metabolism; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004041:Dietary Fats; D000960:Hypolipidemic Agents; D010840:Phytosterols; D012855:Sitosterols; D014280:Triglycerides; C407042:plant stanol ester; C021273:campesterol; C025473:gamma-sitosterol; D013185:Squalene; C001521:lathosterol; D008383:Margarine; D002784:Cholesterol